An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The list price for Wegovy is $1,349.02 per injection while Ozempic’s list price is $997.58 per injection, which is cost prohibitive for many people who can benefit from these drugs. Insurance ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it ...

List prices exceed $1,000 per month and spotty insurance ... Novo Nordisk sells the drug semaglutide under the brands Ozempic for diabetes and Wegovy for weight loss. The company's older weight ...